Pfizer's Centers for Therapeutic Innovation (CTI) represents a significant departure from the traditional lengthy and linear process of target discovery to eventual drug development. Collaborations such as the one between CTI Boston and Dr. Hal Dvorak of Beth Israel Deaconess Medical Center exemplify this new model, which seeks to expedite the translation of science into medicine.
CTI's open innovation model puts Pfizer scientists side by side with academic investigators in the lab, where they share their understanding of target biology and translational medicine expertise. Pfizer funds preclinical and clinical development programs and offers equitable intellectual property and ownership rights to our CTI partners. In addition, we provide access to select Pfizer compound libraries, proprietary screening methods, antibody development technologies, and a wealth of dedicated resources and support from Pfizer experts in drug development and protein sciences.
The ultimate goal of each collaboration is to validate a drug candidate that can be moved into further clinical testing.